Hints and tips:
...The leader of the pack was Teva Pharmaceuticals, whose market capitalisation reached $60bn in 2015. Teva now sits in the crosshairs of law enforcement....
...Instead, Teva will use its new debt largely to repay other outstanding debt that comes due from next year....
...Teva declined to comment. Lumen and UltraTech did not respond to a request for comment. *This story has been amended to indicate that Teva is an Israel-based drugmaker....
...In the case of Teva’s Copaxone, the patent on the underlying medication, glatiramer acetate, expired in 2015....
...Teva posted its first-quarter earnings on Wednesday, reporting adjusted earnings per share of 63 cents, beating analysts’ expectations of earnings per share of 59 cents....
...The biggest concern has been around the minimal penalties for issuers who don’t hit their targets: drugmaker Teva, for example, would be on the hook for only an extra $10mn if it misses goals linked to a...
...The EU accused Teva and Cephalon over the agreement in 2017 and brought formal charges this year. The EU started its probe when Teva acquired Cephalon....
...Glenmark, an alleged co-conspirator of Teva, is awaiting trial....
...On Tuesday, Israel’s Teva became the seventh drugmaker to be charged in the US with conspiring to fix the price of generic drugs....
...“If you look at the history of Teva, there were a lot of profit warnings before I joined....
...To boost supplies of antimalarials, generics manufacturers Teva and Novartis’ Sandoz have pledged to donate millions of doses to US hospitals....
...Teva revised its full-year guidance to the top end of its prior range....
...But Teva reported a net loss of $689m, widening from $241m the year before, as profit in North America fell 30 per cent....
...Shares in Teva jumped 9 per cent in late afternoon trading in New York, while Johnson & Johnson stock was flat....
...Teva Pharmaceuticals, the only remaining manufacturer, fell 1.6 per cent to $7.38, after losing 3.5 per cent during the trading day....
...Teva and the state government finalised the deal ahead of a trial, which was scheduled to begin on Tuesday....
...Revenues in the US, Teva’s largest market, fell 20 per cent to $1.9bn. Teva lost $105m in the quarter, compared with net income of $1bn in the same quarter the year before....
...Shares in Teva were down 7.1 per cent to $17.76 by mid-morning in New York....
...Teva got a shot in the arm on Thursday from the long-awaited approval by US regulators of its generic version of Mylan’s EpiPen allergy injector....
...The new Teva boss says the correct ratio should be below two times. This newly humbled Teva will not approach its previous heights any time soon....
...Teva US-listed shares are up 2 per cent year-to-date, having tumbled more than 50 per cent last year....
...Friday’s downgrade leaves Teva’s rating at Ba2, from Baa3....
...Mr Netanyahu insisted that Teva remained headquartered in Israel, and try to keep as many factories open in Jerusalem....
...Teva is scheduled tomorrow to announce a restructuring plan and “additional measures to improve its business and financial performance.”...
...While overall revenue for the third quarter rose 1 per cent year-on-year, sales at Teva’s generics business suffered an 8 per cent drop....
International Edition